On June 25, 2026, UpDoc Inc., a clinical AI company, announced that it received clearance from FDA for what the company describes as the first Software as a Medical Device (SaMD) that uses patient-facing large language models (LLMs). UpDoc describes
One-Stop Shop
The Latest Trends in Consumer Products & Retail
The One-Stop Shop blog, published by McGuireWoods LLP, covers a range of legal topics including consumer arbitration agreements, data privacy regulations such as the California Consumer Privacy Act, and enforcement actions related to product labeling like "Made in USA" claims. It also addresses regulatory developments in areas like FDA inspections of foreign manufacturing facilities and enforcement trends under the False Claims Act. The blog provides updates and analysis relevant to businesses navigating compliance, regulatory enforcement, and litigation risks across various industries.
Going Beyond Federal Class Action Rule Kills Virginia’s Bill — For Now
On May 19, 2026, Virginia Gov. Abigail Spanberger announced that she intends to veto what would have been Virginia’s first class action statute. Virginia and Mississippi remain the only two states without a class action mechanism.
Class actions in Virginia…
U.S. Court Blocks Texas Food Labeling Statute; Manufacturers Should Watch Appeal
A federal court blocked the enforcement of a Texas law requiring food manufacturers to place conspicuous warning labels on products containing one or more of the statute’s listed ingredients. The court’s decision in American Beverage Association, et al. v. Paxton, Case…
As FTC Increases Enforcement of Made in USA Claims, Companies Should Prepare for More Regulatory Attention
On March 13, 2026, the Trump administration issued an executive order directing the Federal Trade Commission (FTC) to prioritize enforcement actions against unlawful Made in USA statements, signaling heightened scrutiny of country-of-origin representations. In the wake of this directive, on…
White House Releases AI Legislative Recommendations—Congress Has the Blueprint, but Questions Remain
On March 20, 2026, the White House unveiled its National Policy Framework for Artificial Intelligence, providing a blueprint on legislative recommendations and urging Congress to act. It recommends that Congress create a unified federal standard to reduce the regulatory friction…
FDA and EMA Provide Guiding Principles for AI in Drug Development
On Jan. 14, 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly released the “Guiding Principles of Good AI Practice in Drug Development,” a set of 10 high-level principles intended to steer the safe…
California Bill Limiting Scope of Consumer Arbitration Agreements to Goods or Services at Issue Becomes Law
California SB 82 — a bill that seeks to end “infinite” arbitration clauses and limit the scope of consumer arbitration agreements to the “use, payment, or provision of the good, service, money, or credit provided by that consumer use agreement”…
New CCPA Rules Are Here: Is Your Business Ready for What’s Next?
In a significant step toward strengthening consumer privacy protections, the California Privacy Protection Agency (CPPA) board adopted a comprehensive set of updates to the California Consumer Privacy Act regulations. These long-anticipated regulations — covering cybersecurity audits, risk assessments and automated decision-making…
FTC Signals Continued Enforcement of “Made in USA” Labeling Rule and Guidance
The Federal Trade Commission was quiet in its role as the Made in USA enforcement authority during the first few months of the Trump administration. But July left little doubt that the current FTC will continue the robust activity of…
FDA to Expand Unannounced Inspections of Foreign Facilities — Manufacturers, Research Firms Should Prepare
medical products intended for American consumers and patients. The FDA stated that this new inspection strategy will ensure that foreign manufacturers receive the same level of oversight and regulatory scrutiny as domestic companies. Key aspects of the FDA’s plan include:…